Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Core MSCI Emerging Markets ETF (IEMG) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

iShares Core MSCI Emerging Markets ETFTrade
Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

iShares Core MSCI Emerging Markets ETF vs Neurocrine Biosciences Inc — how do they compare? iShares Core MSCI Emerging Markets ETF trades at $81.11, while Neurocrine Biosciences Inc trades at $156.22 (market cap $16.46B). The key difference: iShares Core MSCI Emerging Markets ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.

IEMGNBIX
Sector
Broad Market / FactorHealth
52-Week High
$86.00$185.50
52-Week Low
$61.76$123.10
Market Cap
$16.46B
Enterprise Value
$16.48B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Core MSCI Emerging Markets ETF

IEMG trades at $81.02, up 1.84% today with a bullish technical signal from moving averages. The ETF shows strong momentum with 35% returns over the past year, driven by emerging market exposure and a 40% technology weighting focused on AI themes. Recent news highlights IEMG's outperformance versus developed market ETFs and its competitive 0.09% expense ratio.

Outlook remains positive given emerging market growth potential and AI-driven tech exposure, though risks include concentration in volatile emerging economies and elevated RSI levels suggesting potential near-term consolidation. The ETF's valuation discount to US equities and strong institutional inflows support continued investor interest.

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $156.49, down 5.11% amid bearish technical signals despite strong fundamentals. The stock shows robust revenue growth with Q2 2026 sales up 39% year-over-year to $959 million, beating earnings estimates. Recent news highlights pipeline advancement with a Phase 1 GLP-1/GIP/glucagon agonist study initiation while facing safety concerns for Vykat XR in Prader-Willi syndrome.

Outlook remains positive with 86% analyst buy ratings and $208.82 consensus target offering 33% upside. Key risks include drug safety scrutiny and execution on pipeline catalysts. Strong institutional interest persists with CalPERS increasing holdings by 13% in Q2 2026, supporting long-term growth narrative amid near-term technical weakness.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares Core MSCI Emerging Markets ETF

IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.

Read more on IEMG

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX